Another fianlimab fiasco for Regeneron
The company discontinues the Lag3 project in lung cancer.
Replimune’s fight with the FDA deepens
The oncolytic virus vuso-vec is slapped with its second CRL.
Immatics’ PRAME T-cell engager improves
The response rate jumps to 30% with higher doses of IMA402.
Moderna takes on IO Biotech
The group is expanding its mRNA-4359 trial to include first-line melanoma.
More delays for Regeneron
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
FDA red and green lights: July 2025
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
Scancell pivots back to a subgroup
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
